Abstract: Objective： To evaluate the safety and efficacy of Breviscapine dripping pill in the treatment of apoplectic sequela. Methods： 240 patients with apoplexy sequelae who received treatment. The clinical trial was Randomized， double-blind， double-dummy， positive drug parallel control and multi-center. 180 patients in the test group and 60 patients in the control group. The effects and adverse reactions of the two groups on day 0 and day 84 of visit were evaluated. Results： Compared with pre-treatment， the NIHSS of the test group decreased by 4.7 on average， and the Barthel index of daily living self-care ability changed by -21.2 which was significantly higher than that of the control group (P<0.000 1). There were no adverse events in the test group， and the incidence of adverse events in the control group was 1.67%. Conclusion： Breviscapine dropping pill is safe and effective in treating apoplectic sequela caused by blood stasis.